Zoryve (Roflumilast) for Psoriasis

Overview
Zoryve is approved by the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis of the scalp and body in adults and children 12 years of age and older. People with plaque psoriasis (a chronic autoimmune condition that causes thick, scaly patches on the skin) may be prescribed Zoryve if they have lesions on the scalp or body. Zoryve is also known by its drug name, roflumilast.

Zoryve belongs to a class of medications called phosphodiesterase 4 (PDE4) inhibitors. It is believed to work by reducing inflammation in the skin, which helps relieve discoloration, itching, and scaling associated with plaque psoriasis.

How do I take it?
Prescribing information states that Zoryve is applied as a topical foam once daily to the affected areas of the scalp or body. It is for external use only and should not be used in the eyes, mouth, or vaginal area. The medication should be used exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Zoryve include headache, diarrhea, nausea, and nasopharyngitis (inflammation of the nose and throat).

Rare but serious side effects may include increased risk of adverse reactions when used with certain medications that affect how roflumilast is processed in the body, such as systemic CYP3A4 inhibitors or certain hormonal contraceptives. Use with these medications should be carefully considered by a health care provider. The product is also flammable; exposure to fire or smoking should be avoided during and shortly after application.

For more information about this treatment, visit:
Zoryve (Roflumilast) Foam, 0.3% — Arcutis Biotherapeutics